Clinical Trial Results: Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for an RSV vaccine candidate encapsulated in a lipid nanoparticle formulation in adults 18-50 and 60+ completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Immunization

Drugs mentioned

• RSV vaccine candidate encapsulated in a lipid nanoparticle formulation

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Immunization | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-08-05